CO7131377A2 - Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos - Google Patents

Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos

Info

Publication number
CO7131377A2
CO7131377A2 CO14251787A CO14251787A CO7131377A2 CO 7131377 A2 CO7131377 A2 CO 7131377A2 CO 14251787 A CO14251787 A CO 14251787A CO 14251787 A CO14251787 A CO 14251787A CO 7131377 A2 CO7131377 A2 CO 7131377A2
Authority
CO
Colombia
Prior art keywords
mif
combination therapy
chemotherapeutic antibodies
chemotherapeutic
antibodies
Prior art date
Application number
CO14251787A
Other languages
English (en)
Inventor
Randolf Kerschbaumer
Friedrich Scheiflinger
Hartmut Ehrlich
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48625989&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7131377(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of CO7131377A2 publication Critical patent/CO7131377A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La presente invención se refiere a usos terapéuticos de las proteínas del factor de crecimiento del 5 fibroblasto humano 21 (FGF21).
CO14251787A 2012-04-16 2014-11-13 Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos CO7131377A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624964P 2012-04-16 2012-04-16
US201261668932P 2012-07-06 2012-07-06
US201361778094P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
CO7131377A2 true CO7131377A2 (es) 2014-12-01

Family

ID=48625989

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14251787A CO7131377A2 (es) 2012-04-16 2014-11-13 Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos

Country Status (16)

Country Link
US (1) US20150071942A1 (es)
EP (2) EP2838561A1 (es)
JP (2) JP2015514735A (es)
KR (2) KR20150027048A (es)
CN (2) CN104812411A (es)
AU (1) AU2013202693B2 (es)
BR (1) BR112014025855A8 (es)
CA (1) CA2869990A1 (es)
CL (2) CL2014002788A1 (es)
CO (1) CO7131377A2 (es)
HK (1) HK1206985A1 (es)
IL (2) IL235038A0 (es)
MX (1) MX2014012535A (es)
NZ (1) NZ628363A (es)
RU (2) RU2014145887A (es)
WO (1) WO2013156473A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11402388B2 (en) 2012-07-10 2022-08-02 Takeda Pharmaceutical Company Limited Anti-MIF immunohistochemistry
US10613100B2 (en) * 2014-01-03 2020-04-07 Baxalta Incorporated Anti-MIF immunohistochemistry
EP3277718B1 (en) 2015-03-31 2021-03-24 Baxalta GmbH Dosage regimen for anti-mif antibodies
US20180155419A1 (en) 2015-05-18 2018-06-07 Baxalta GmbH Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030615A (en) * 1993-05-17 2000-02-29 The Picower Institute For Medical Research Combination method for treating diseases caused by cytokine-mediated toxicity
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
JP4708510B2 (ja) * 1993-05-17 2011-06-22 サイトカイン ファーマサイエンシズ，インコーポレーテッド サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
AU2004204778B2 (en) * 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
RU2389507C2 (ru) * 2004-07-02 2010-05-20 Ньютек Фарма Плс Лечение рака
CA2633486C (en) * 2005-12-16 2015-02-03 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
NZ586600A (en) * 2008-01-04 2012-05-25 Baxter Int Anti macrophage migration inhibitory factor antibodies
EP2525820B1 (en) * 2010-01-19 2016-05-11 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
JP2014530360A (ja) * 2011-10-07 2014-11-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 診断マーカーとしてのｏｘＭＩＦ
EP2753937B1 (en) * 2011-10-07 2018-01-17 Baxalta GmbH Characterization of cho-mif gene and protein, and use thereof

Also Published As

Publication number Publication date
HK1206985A1 (en) 2016-01-22
RU2014145887A (ru) 2016-06-10
CL2016001327A1 (es) 2017-01-06
NZ628363A (en) 2017-02-24
US20150071942A1 (en) 2015-03-12
KR20160049047A (ko) 2016-05-04
RU2016117260A3 (es) 2018-10-23
CN106139143A (zh) 2016-11-23
RU2016117260A (ru) 2018-10-23
CN104812411A (zh) 2015-07-29
AU2013202693B2 (en) 2015-01-22
BR112014025855A2 (es) 2017-06-20
JP2015514735A (ja) 2015-05-21
EP2838561A1 (en) 2015-02-25
IL245604A0 (en) 2016-06-30
IL235038A0 (en) 2014-12-31
WO2013156473A1 (en) 2013-10-24
CA2869990A1 (en) 2013-10-24
CL2014002788A1 (es) 2015-02-06
AU2013202693A1 (en) 2013-10-31
BR112014025855A8 (pt) 2017-07-25
MX2014012535A (es) 2015-04-10
JP2016175918A (ja) 2016-10-06
EP3064221A1 (en) 2016-09-07
KR20150027048A (ko) 2015-03-11

Similar Documents

Publication Publication Date Title
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
PE20150201A1 (es) Proteinas del factor 21 de crecimiento del fibroblasto
CY1119840T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
EA201500314A1 (ru) Лекарственные формы энзалутамида
ECSP19020740A (es) Anticuerpos anti-cd27
CR20130134A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
CO7020878A2 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
DOP2015000012A (es) Acidos 5-aminotetrahidroquinolin-2-carboxilicos novedosos y su uso
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EP3148569A4 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
EA201591133A1 (ru) СОСТАВЫ В ВИДЕ РАСТВОРА СКОНСТРУИРОВАННЫХ АНТИТЕЛ К IL-23p19
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
CO7131377A2 (es) Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos
MX2017001433A (es) Sistema de bioprocesamiento a microescala y metodo para fabricacion de proteina a partir de sangre humana.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
EA201301300A3 (ru) Фармацевтическая композиция в форме пероральной суспензии, которая содержит фракцию флавоноида и ксантановую камедь
EA201370204A1 (ru) Варианты нейротрофического фактора глиальных клеток (gdnf) человека
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение
CY1117740T1 (el) Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης